MA53837A - Tetrahydro-pyrido[3,4-b]indoles modulateurs des récepteurs des oestrogènes et leurs utilisations - Google Patents
Tetrahydro-pyrido[3,4-b]indoles modulateurs des récepteurs des oestrogènes et leurs utilisationsInfo
- Publication number
- MA53837A MA53837A MA053837A MA53837A MA53837A MA 53837 A MA53837 A MA 53837A MA 053837 A MA053837 A MA 053837A MA 53837 A MA53837 A MA 53837A MA 53837 A MA53837 A MA 53837A
- Authority
- MA
- Morocco
- Prior art keywords
- indoles
- pyrido
- tetrahydro
- estrogen receptor
- receptor modulators
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462093929P | 2014-12-18 | 2014-12-18 | |
| US201562110998P | 2015-02-02 | 2015-02-02 | |
| US201562142077P | 2015-04-02 | 2015-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53837A true MA53837A (fr) | 2021-11-10 |
Family
ID=54850193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053837A MA53837A (fr) | 2014-12-18 | 2015-12-17 | Tetrahydro-pyrido[3,4-b]indoles modulateurs des récepteurs des oestrogènes et leurs utilisations |
Country Status (33)
Families Citing this family (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX388871B (es) | 2014-06-27 | 2025-03-20 | Nogra Pharma Ltd | Moduladores del receptor arilo y metodos para elaborar y usar los mismos. |
| EP3233828B1 (en) | 2014-12-18 | 2020-03-04 | F. Hoffmann-La Roche AG | Estrogen receptor modulators and uses thereof |
| KR20250044939A (ko) | 2014-12-18 | 2025-04-01 | 에프. 호프만-라 로슈 아게 | 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도 |
| LT3355884T (lt) * | 2015-10-01 | 2021-07-26 | Olema Pharmaceuticals, Inc. | Tetrahidro-1h-pirido[3,4-b]indolo antiestrogeniniai vaistai |
| JP2019001715A (ja) * | 2015-10-30 | 2019-01-10 | 協和発酵キリン株式会社 | 三環性化合物 |
| EP3386968B1 (en) | 2015-12-09 | 2025-04-02 | The Board of Trustees of the University of Illinois | Benzothiophene-based selective estrogen receptor downregulator compounds |
| AU2017213614B2 (en) * | 2016-02-05 | 2022-09-01 | Inventisbio Llc | Selective estrogen receptor degraders and uses thereof |
| UY37124A (es) | 2016-02-15 | 2017-09-29 | Sanofi Sa | Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos |
| WO2017182493A1 (en) | 2016-04-20 | 2017-10-26 | Astrazeneca Ab | Indazole derivatives for use in down-regulation of the estrogen receptor for the treatment of cancer |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| CN109311876B (zh) * | 2016-06-16 | 2022-05-03 | 豪夫迈·罗氏有限公司 | 杂芳基雌激素受体调节剂及其用途 |
| WO2017216280A1 (en) * | 2016-06-16 | 2017-12-21 | F. Hoffmann-La Roche Ag | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF |
| CN107543871A (zh) * | 2016-06-29 | 2018-01-05 | 重庆华邦胜凯制药有限公司 | 分离测定帕布昔利布中间体z1及其有关物质的方法 |
| CA3028751A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based antiproliferative agents |
| WO2018019793A1 (en) * | 2016-07-25 | 2018-02-01 | Astrazeneca Ab | N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer |
| SG10202104282SA (en) * | 2016-09-27 | 2021-06-29 | Radius Pharmaceuticals Inc | Methods for treating ovarian cancer |
| DK3433256T3 (da) * | 2016-10-24 | 2019-10-28 | Astrazeneca | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinolinderivat, der er anvendeligt til behandling af cancer |
| WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
| CN110139863B (zh) * | 2016-10-28 | 2022-02-18 | 罗欣健康科技发展(北京)有限公司 | 作为雌激素受体降解剂的吲哚并取代哌啶类化合物 |
| RU2742278C2 (ru) * | 2016-11-17 | 2021-02-04 | Санофи | Новые соединения замещенного n-(3-фторпропил)пирролидина, способы их получения и их терапевтическое применение |
| WO2018108954A1 (en) | 2016-12-12 | 2018-06-21 | F. Hoffmann-La Roche Ag | Process for the preparation of 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol |
| EA037533B9 (ru) * | 2016-12-16 | 2021-05-27 | Астразенека Аб | 6,7,8,9-ТЕТРАГИДРО-3H-ПИРАЗОЛО[4,3-f]ИЗОХИНОЛИНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ РАКА |
| AU2018205262A1 (en) | 2017-01-06 | 2019-07-11 | G1 Therapeutics, Inc. | Combination therapy for the treatment of cancer |
| WO2018130123A1 (zh) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的五环类化合物及其应用 |
| WO2018138739A1 (en) | 2017-01-27 | 2018-08-02 | Sun Pharma Advanced Research Company Limited | Novel antiestrogenic heterocyclic compounds |
| ES2766249T3 (es) * | 2017-01-30 | 2020-06-12 | Astrazeneca Ab | Moduladores del receptor de estrógeno |
| EP3580223A4 (en) | 2017-02-10 | 2021-01-06 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| MX392531B (es) | 2017-06-29 | 2025-03-24 | G1 Therapeutics Inc | Formas morficas de g1t38 y metodos de preparacion de las mismas. |
| EP3434272A1 (en) | 2017-07-25 | 2019-01-30 | Sanofi | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
| WO2019096106A1 (zh) * | 2017-11-14 | 2019-05-23 | 杭州安霖药业有限公司 | 杂环化合物及其在医药上的应用 |
| EA038160B1 (ru) * | 2017-11-30 | 2021-07-15 | Астразенека Аб | Модуляторы рецептора эстрогена |
| US10519152B2 (en) | 2017-12-21 | 2019-12-31 | Astrazeneca Ab | Compounds and their use in treating cancer |
| KR102766460B1 (ko) | 2018-01-22 | 2025-02-11 | 래디어스 파마슈티컬스, 인코포레이티드 | 에스트로겐 수용체-조절 화합물 |
| WO2019192533A1 (zh) * | 2018-04-04 | 2019-10-10 | 深圳福沃药业有限公司 | 用于治疗乳腺癌的雌激素受体降解剂 |
| CN112566666A (zh) | 2018-05-14 | 2021-03-26 | 努瓦申生物公司 | 靶向抗癌核激素受体的化合物 |
| JP6916969B1 (ja) | 2018-06-21 | 2021-08-11 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ３−（（１Ｒ，３Ｒ）−１−（２，６−ジフルオロ−４−（（１−（３−フルオロプロピル）アゼチジン−３−イル）アミノ）フェニル）−３−メチル−１，３，４，９−テトラヒドロ−２Ｈ−ピリド［３，４−ｂ］インドール−２−イル）−２，２−ジフルオロプロパン−１−オールの固体形態及び置換されたフェニル又はピリジニル部分を含む縮合三環式化合物を調製するための方法とそれらの使用方法 |
| TWI702219B (zh) * | 2018-07-12 | 2020-08-21 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
| EP3837548A2 (en) * | 2018-08-17 | 2021-06-23 | F. Hoffmann-La Roche AG | Diagnostic and therapeutic methods for the treatment of breast cancer |
| TW202026280A (zh) | 2018-09-07 | 2020-07-16 | 法商賽諾菲公司 | 6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧基苯基]-8,9-二氫-7h-苯並[7]輪烯-2-甲酸甲酯的鹽及其製備方法 |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CN120698985A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| CA3128521A1 (en) * | 2019-02-27 | 2020-09-03 | Millennium Pharmaceuticals, Inc. | Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors |
| AU2020274113A1 (en) | 2019-05-14 | 2021-11-11 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| WO2020254289A1 (en) * | 2019-06-17 | 2020-12-24 | Ucb Pharma Gmbh | N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis |
| CA3144791A1 (en) * | 2019-07-07 | 2021-01-14 | Olema Pharmaceuticals, Inc. | Regimens of estrogen receptor antagonists |
| BR112022000553A2 (pt) | 2019-07-22 | 2022-05-17 | Radius Pharmaceuticals Inc | Compostos moduladores do receptor de estrogênio |
| BR112022002138A2 (pt) | 2019-08-06 | 2022-04-19 | Recurium Ip Holdings Llc | Moduladores do receptor de estrogênio para tratamento de mutantes |
| US20220370625A1 (en) * | 2019-09-19 | 2022-11-24 | Totus Medicines Inc. | Therapeutic conjugates |
| WO2021097046A1 (en) | 2019-11-13 | 2021-05-20 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| PE20221724A1 (es) | 2019-12-20 | 2022-11-04 | C4 Therapeutics Inc | Compuestos de isoindolinona e indazol para la degradacion del receptor del factor de crecimiento epidermico (egfr) |
| IL294074A (en) * | 2019-12-20 | 2022-08-01 | Recurium Ip Holdings Llc | conjunctions |
| TW202140475A (zh) * | 2020-01-16 | 2021-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合醯亞胺類衍生物、其製備方法及其在醫藥上的應用 |
| TW202140448A (zh) * | 2020-01-16 | 2021-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 並環醯亞胺類衍生物、其製備方法及其在醫藥上的應用 |
| TW202146007A (zh) | 2020-02-27 | 2021-12-16 | 法商賽諾菲公司 | 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合 |
| WO2021178920A1 (en) | 2020-03-05 | 2021-09-10 | C4 Therapeutics, Inc. | Compounds for targeted degradation of brd9 |
| CN115175679A (zh) | 2020-03-06 | 2022-10-11 | 奥列马制药公司 | 治疗雌激素受体相关疾病的方法 |
| WO2021213358A1 (zh) * | 2020-04-21 | 2021-10-28 | 江苏先声药业有限公司 | 含硼化合物及其应用 |
| IL297216A (en) | 2020-04-24 | 2022-12-01 | Astrazeneca Ab | Dosage regimen for the treatment of cancer |
| KR20230005270A (ko) | 2020-04-24 | 2023-01-09 | 아스트라제네카 아베 | 약학적 제형 |
| EP4149476A1 (en) | 2020-05-12 | 2023-03-22 | Genentech, Inc. | Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor |
| US20230348459A1 (en) * | 2020-05-15 | 2023-11-02 | Simcere Pharmaceutical Co., Ltd. | Pyrrolidine compound and use thereof |
| WO2021249533A1 (zh) * | 2020-06-12 | 2021-12-16 | 江苏先声药业有限公司 | 雌激素受体调节剂化合物及其用途 |
| WO2022005943A2 (en) | 2020-06-30 | 2022-01-06 | Genentech, Inc. | Processes for making serd tricyclic compounds having a substituted phenyl or pyridinyl moiety |
| IL300397A (en) | 2020-08-05 | 2023-04-01 | C4 Therapeutics Inc | Compounds for targeted knockdown of RET |
| CN114105977B (zh) * | 2020-08-28 | 2023-09-01 | 先声再明医药有限公司 | 雌激素受体调节剂化合物及其用途 |
| JP2024502270A (ja) | 2020-12-23 | 2024-01-18 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | エストロゲン受容体調節薬 |
| WO2022166983A1 (zh) * | 2021-02-08 | 2022-08-11 | 贝达药业股份有限公司 | 杂芳基并哌啶类衍生物及其药物组合物和应用 |
| JP2024516024A (ja) | 2021-05-03 | 2024-04-11 | ニューベイション・バイオ・インコーポレイテッド | 抗がん核内ホルモン受容体標的化化合物 |
| MX2023014059A (es) | 2021-06-08 | 2024-03-12 | C4 Therapeutics Inc | Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante. |
| CN117813288A (zh) * | 2021-07-15 | 2024-04-02 | 西藏海思科制药有限公司 | 芳氨基衍生物雌激素受体调节剂及其用途 |
| KR102689151B1 (ko) * | 2021-09-06 | 2024-07-29 | 연세대학교 산학협력단 | Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물 |
| KR20240116710A (ko) * | 2021-10-08 | 2024-07-30 | 아조라 테라퓨틱스 인코포레이티드 | 아릴 탄화수소 수용체 작용제의 유도체 |
| CN118119620A (zh) * | 2021-11-12 | 2024-05-31 | 南京再明医药有限公司 | 用于治疗肿瘤的药物组合及其应用 |
| WO2023091550A1 (en) * | 2021-11-18 | 2023-05-25 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
| US12410155B2 (en) | 2021-12-28 | 2025-09-09 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | Salt form and crystal form of tetrahydrocyclohepta indazole compound |
| CN116804008A (zh) * | 2022-03-24 | 2023-09-26 | 烟台创和生物科技有限公司 | 雌激素受体降解剂及其制备方法和应用 |
| US20250282775A1 (en) | 2022-04-28 | 2025-09-11 | Hoffmann-La Roche Inc. | Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate |
| WO2023221123A1 (en) * | 2022-05-20 | 2023-11-23 | Olema Pharmaceuticals, Inc. | Crystalline forms of an estrogen receptor antagonist |
| WO2023221122A1 (en) * | 2022-05-20 | 2023-11-23 | Olema Pharmaceuticals, Inc. | Salts and solid forms of an estrogen receptor antagonist |
| WO2024015506A1 (en) * | 2022-07-14 | 2024-01-18 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-mediated disorders |
| WO2024017131A1 (zh) * | 2022-07-21 | 2024-01-25 | 贝达药业股份有限公司 | 杂芳基并哌啶类衍生物及其药物组合物和应用 |
| CN115109058B (zh) * | 2022-07-27 | 2023-04-07 | 黑龙江中医药大学 | 一种用于治疗胃癌的药物及其制备方法 |
| KR20250055538A (ko) | 2022-08-03 | 2025-04-24 | 브리스톨-마이어스 스큅 컴퍼니 | Ret 단백질을 조정하기 위한 화합물 |
| WO2024039860A1 (en) * | 2022-08-19 | 2024-02-22 | Olema Pharmaceuticals, Inc. | 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer |
| EP4573091A1 (en) * | 2022-08-19 | 2025-06-25 | Olema Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| JP2025528250A (ja) * | 2022-08-25 | 2025-08-26 | サノフイ | 新規な置換２，３，４，９－テトラヒドロ－１ｈ－ピリド［３，４－ｂ］インドールカルボン酸誘導体、その調製方法及びその治療用途 |
| CN120051280A (zh) | 2022-10-17 | 2025-05-27 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的serd的组合 |
| TW202425966A (zh) * | 2022-10-28 | 2024-07-01 | 大陸商南京再明醫藥有限公司 | 用於治療腫瘤的藥物組合、藥物組成物及其用途 |
| US20250376474A1 (en) | 2022-11-04 | 2025-12-11 | Bristol-Myers Squibb Company | Ret-ldd protein degraders |
| CN120530116A (zh) | 2022-11-04 | 2025-08-22 | 百时美施贵宝公司 | Ret-ldd蛋白抑制剂 |
| JP2025539034A (ja) | 2022-11-11 | 2025-12-03 | アストラゼネカ・アクチエボラーグ | 癌の治療のための併用療法 |
| US20240180893A1 (en) | 2022-11-17 | 2024-06-06 | Astrazeneca Ab | Methods of treatment of breast cancer |
| CN115894485B (zh) * | 2023-03-03 | 2023-06-27 | 山东绿叶制药有限公司 | 杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用 |
| US11773092B1 (en) | 2023-03-27 | 2023-10-03 | King Faisal University | Pyrido[3,4-b]indol-1-one compounds as antibacterial agents |
| TW202508573A (zh) | 2023-05-11 | 2025-03-01 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合療法 |
| WO2025006753A2 (en) | 2023-06-30 | 2025-01-02 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
| WO2025103409A1 (zh) * | 2023-11-16 | 2025-05-22 | 南京同诺康医药科技有限公司 | Nmt抑制剂及其制备方法和用途 |
| CN118791392A (zh) * | 2024-06-18 | 2024-10-18 | 华中科技大学 | 一种合成依拉司群的方法及中间体化合物 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE398789C (de) | 1923-03-03 | 1924-07-15 | L V Kramolin | Verfahren und Einrichtung zur Verhinderung des Mithoerens beim Telephon- und Telegraphenverkehr mittels elektrischer Wellen und zum Vielfachverkehr mittels elektromagnetischer Wellen |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| SE455604B (sv) | 1982-06-29 | 1988-07-25 | Stiftelsen Ind Organisk Elektr | Sett att framstella fenetylaminer medelst elektrokemisk reduktion |
| US5206377A (en) | 1991-12-05 | 1993-04-27 | Whitby Research, Inc. | Compounds useful as antiproliferative agents |
| EP0620222A3 (en) | 1993-04-14 | 1995-04-12 | Lilly Co Eli | Tetrahydro-beta-carbolines. |
| IL115582A0 (en) * | 1994-10-14 | 1996-01-19 | Lilly Co Eli | Methods for treating resistant tumors |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| ES2241902T3 (es) | 2000-12-08 | 2005-11-01 | Smithkline Beecham Corporation | Compuestos antibacterianos. |
| WO2002064590A2 (en) | 2001-02-12 | 2002-08-22 | Lilly Icos Llc | Carboline derivatives |
| US6951961B2 (en) | 2002-05-17 | 2005-10-04 | Marina Nikolaevna Protopopova | Methods of use and compositions for the diagnosis and treatment of infectious disease |
| TWI329111B (en) | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
| EP1618090A1 (en) | 2003-04-11 | 2006-01-25 | Novo Nordisk A/S | 11ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS |
| EP1670314A4 (en) | 2003-09-05 | 2009-02-25 | Sequella Inc | METHODS AND COMPOSITIONS INCLUDE DIAMINE AS A NEW THERAPEUTIC FOR TUBERCULOSIS |
| US8076352B2 (en) * | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| US8076353B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Inhibition of VEGF translation |
| US7767689B2 (en) | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
| SG184755A1 (en) * | 2004-03-15 | 2012-10-30 | Ptc Therapeutics Inc | Carboline derivatives useful in the inhibition of angiogenesis |
| WO2006015035A1 (en) | 2004-08-02 | 2006-02-09 | Smithkline Beecham Corporation | Useful compounds for hpv infection |
| WO2007002051A1 (en) | 2005-06-22 | 2007-01-04 | Smithkline Beecham Corporation | Carboline derivatives and their use as inhibitors of flaviviridae infections |
| SI1934174T1 (sl) | 2005-10-07 | 2011-08-31 | Exelixis Inc | Inhibitorji MEK in postopki za njihovo uporabo |
| PT2201840E (pt) | 2006-09-22 | 2012-02-14 | Pharmacyclics Inc | Inibidores da tirosina quinase de bruton |
| CA2683444A1 (en) | 2007-04-13 | 2008-10-23 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| EA019601B1 (ru) | 2008-04-29 | 2014-04-30 | Новартис Аг | Производные спироиндола, предназначенные для лечения паразитарных заболеваний |
| US9292307B2 (en) | 2008-07-30 | 2016-03-22 | Kyocera Corporation | User interface generation apparatus |
| US20110195929A1 (en) | 2008-08-05 | 2011-08-11 | Summit Corporation Plc | Compounds for the treatment of flaviviral infections |
| US20110237538A1 (en) | 2008-08-06 | 2011-09-29 | Summit Corporation Plc | Treatment of lysosomal storage disorders and other proteostatic diseases |
| WO2010029313A1 (en) | 2008-09-11 | 2010-03-18 | Summit Corporation Plc. | Antiinfective compounds |
| WO2010049678A2 (en) | 2008-10-31 | 2010-05-06 | Summit Corporation Plc | Treatment of energy utilization diseases |
| WO2010075282A1 (en) | 2008-12-22 | 2010-07-01 | University Of Washington | Molecular inhibitors of the wnt/beta-catenin pathway |
| WO2010075286A1 (en) | 2008-12-24 | 2010-07-01 | University Of Washington | MOLECULAR ACTIVATORS OF THE Wnt/β-CATENIN PATHWAY |
| WO2010107485A1 (en) | 2009-03-17 | 2010-09-23 | The Trustees Of Columbia University In The City Of New York | E3 ligase inhibitors |
| US8497276B2 (en) | 2009-03-31 | 2013-07-30 | Arqule, Inc. | Substituted indolo-piperidine compounds |
| WO2010138652A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating kaposi sarcoma |
| US20120157401A1 (en) * | 2009-05-27 | 2012-06-21 | Ptc Therapeutics, Inc. | Methods for treating neurofibromatosis |
| US20120202801A1 (en) * | 2009-05-27 | 2012-08-09 | Liangxian Cao | Methods for treating breast cancer |
| US8703726B2 (en) * | 2009-05-27 | 2014-04-22 | Ptc Therapeutics, Inc. | Methods for treating prostate conditions |
| WO2010138659A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating brain tumors |
| CA3184380A1 (en) * | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating cancer and non-neoplastic conditions |
| US20130171103A1 (en) | 2010-05-27 | 2013-07-04 | Ptc Therapeutics, Inc. | Methods for treating viral conditions |
| ES2627692T3 (es) | 2010-06-10 | 2017-07-31 | Aragon Pharmaceuticals, Inc. | Moduladores de receptores de estrógenos y usos de los mismos |
| US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| MX2013006858A (es) * | 2010-12-16 | 2013-07-29 | Hoffmann La Roche | Compuesto triciclicos inhibidores de la pi3k y metodos de uso. |
| WO2012084711A1 (en) | 2010-12-24 | 2012-06-28 | Msd Oss B.V. | N-substituted azetidine derivatives |
| EA029559B1 (ru) | 2011-12-14 | 2018-04-30 | Серагон Фармасьютикалс, Инк. | Фторированные модуляторы рецепторов эстрогенов и их применение |
| WO2013142770A1 (en) | 2012-03-23 | 2013-09-26 | Codexis, Inc. | Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs |
| KR102057590B1 (ko) | 2012-03-23 | 2019-12-19 | 노파르티스 아게 | 스피로인돌론을 제조하기 위한 화학적 방법 및 그의 중간체 |
| DE102012209622A1 (de) | 2012-06-08 | 2013-12-12 | Robert Bosch Gmbh | Zahnradmaschine mit hydrodynamisch und hydrostatisch gelagertem Lagerzapfen |
| EP2682119A1 (en) | 2012-07-03 | 2014-01-08 | Université Libre de Bruxelles | Aromatic N-heterocycle derivatives for use as medicine |
| EP2738173A1 (en) | 2012-11-28 | 2014-06-04 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Heterocyclic compounds as inhibitors of the sodium iodide symporter |
| BR112015029455A8 (pt) | 2013-05-28 | 2020-03-17 | Astrazeneca Ab | compostos químicos, uso, métodos e composições para prevenção ou tratamento de câncer |
| MX2015016171A (es) | 2013-06-19 | 2016-08-08 | Seragon Pharmaceuticals Inc | Moduladores del receptor de estrogeno de azetidina y usos de los mismos. |
| EA031077B1 (ru) | 2013-06-19 | 2018-11-30 | Серагон Фармасьютикалз, Инк. | Модулятор рецептора эстрогена и его применения |
| ES2769780T3 (es) | 2013-10-28 | 2020-06-29 | Univ Drexel | Tratamientos novedosos para los trastornos de atención y cognitivos y para la demencia asociada a un trastorno neurodegenerativo |
| US9675586B2 (en) | 2013-12-06 | 2017-06-13 | Genentech, Inc. | Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer |
| BR112016020953A2 (pt) | 2014-03-13 | 2018-01-23 | Hoffmann La Roche | composto, kit, composição farmacêutica, uso de composto, método de tratamento e invenção |
| SG11201607334YA (en) | 2014-03-13 | 2016-10-28 | Hoffmann La Roche | Therapeutic combinations with estrogen receptor modulators |
| MX388871B (es) | 2014-06-27 | 2025-03-20 | Nogra Pharma Ltd | Moduladores del receptor arilo y metodos para elaborar y usar los mismos. |
| EP3233828B1 (en) | 2014-12-18 | 2020-03-04 | F. Hoffmann-La Roche AG | Estrogen receptor modulators and uses thereof |
| KR20250044939A (ko) | 2014-12-18 | 2025-04-01 | 에프. 호프만-라 로슈 아게 | 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도 |
| CN107406433A (zh) | 2014-12-18 | 2017-11-28 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的2,3‑二苯基色烯的衍生物 |
| LT3355884T (lt) | 2015-10-01 | 2021-07-26 | Olema Pharmaceuticals, Inc. | Tetrahidro-1h-pirido[3,4-b]indolo antiestrogeniniai vaistai |
| AU2017213614B2 (en) | 2016-02-05 | 2022-09-01 | Inventisbio Llc | Selective estrogen receptor degraders and uses thereof |
-
2015
- 2015-12-17 KR KR1020257008970A patent/KR20250044939A/ko active Pending
- 2015-12-17 CN CN202011080367.0A patent/CN112375078B/zh active Active
- 2015-12-17 EP EP15810660.9A patent/EP3233852B1/en active Active
- 2015-12-17 PE PE2017001069A patent/PE20171330A1/es unknown
- 2015-12-17 SG SG10202100799PA patent/SG10202100799PA/en unknown
- 2015-12-17 TW TW114103221A patent/TW202534076A/zh unknown
- 2015-12-17 IL IL287326A patent/IL287326B2/en unknown
- 2015-12-17 TW TW113141976A patent/TWI875674B/zh active
- 2015-12-17 MX MX2017007489A patent/MX376763B/es active IP Right Grant
- 2015-12-17 LT LTEP15810660.9T patent/LT3233852T/lt unknown
- 2015-12-17 CA CA2963736A patent/CA2963736A1/en active Pending
- 2015-12-17 IL IL301960A patent/IL301960B2/en unknown
- 2015-12-17 SI SI201531344T patent/SI3233852T1/sl unknown
- 2015-12-17 EA EA201791239A patent/EA032311B1/ru not_active IP Right Cessation
- 2015-12-17 AU AU2015367509A patent/AU2015367509B2/en active Active
- 2015-12-17 CN CN201580069484.8A patent/CN107108611B/zh active Active
- 2015-12-17 DK DK15810660.9T patent/DK3233852T3/da active
- 2015-12-17 IL IL311006A patent/IL311006A/en unknown
- 2015-12-17 HU HUE15810660A patent/HUE050466T2/hu unknown
- 2015-12-17 TW TW111140973A patent/TWI874834B/zh active
- 2015-12-17 WO PCT/EP2015/080119 patent/WO2016097072A1/en not_active Ceased
- 2015-12-17 HR HRP20201396TT patent/HRP20201396T1/hr unknown
- 2015-12-17 TW TW109111355A patent/TWI784255B/zh active
- 2015-12-17 CN CN202311635326.7A patent/CN117865872A/zh active Pending
- 2015-12-17 MY MYPI2017702227A patent/MY198354A/en unknown
- 2015-12-17 CN CN202311635317.8A patent/CN118005631A/zh active Pending
- 2015-12-17 NZ NZ769496A patent/NZ769496A/en unknown
- 2015-12-17 MX MX2020003532A patent/MX395013B/es unknown
- 2015-12-17 KR KR1020237024959A patent/KR102785474B1/ko active Active
- 2015-12-17 CN CN202011079564.0A patent/CN112375077A/zh active Pending
- 2015-12-17 KR KR1020257008973A patent/KR20250044940A/ko active Pending
- 2015-12-17 TW TW104142533A patent/TWI699363B/zh active
- 2015-12-17 PT PT158106609T patent/PT3233852T/pt unknown
- 2015-12-17 EP EP20184866.0A patent/EP3760623A1/en active Pending
- 2015-12-17 MA MA053837A patent/MA53837A/fr unknown
- 2015-12-17 PL PL15810660T patent/PL3233852T3/pl unknown
- 2015-12-17 US US14/972,326 patent/US9980947B2/en active Active
- 2015-12-17 BR BR112017007662-4A patent/BR112017007662B1/pt active IP Right Grant
- 2015-12-17 SG SG10201913913VA patent/SG10201913913VA/en unknown
- 2015-12-17 JP JP2017532740A patent/JP6679147B2/ja active Active
- 2015-12-17 ES ES15810660T patent/ES2819448T3/es active Active
- 2015-12-17 CR CR20170250A patent/CR20170250A/es unknown
- 2015-12-17 SG SG11201704401TA patent/SG11201704401TA/en unknown
- 2015-12-17 KR KR1020177016260A patent/KR102559719B1/ko active Active
- 2015-12-17 RS RS20201092A patent/RS60824B1/sr unknown
- 2015-12-17 CN CN202011080390.XA patent/CN112457310A/zh active Pending
- 2015-12-17 UA UAA201707527A patent/UA122868C2/uk unknown
-
2017
- 2017-03-23 IL IL251370A patent/IL251370B/en active IP Right Grant
- 2017-03-29 CO CONC2017/0003070A patent/CO2017003070A2/es unknown
- 2017-04-04 CL CL2017000814A patent/CL2017000814A1/es unknown
- 2017-06-08 MX MX2022007975A patent/MX2022007975A/es unknown
- 2017-06-16 PH PH12017501140A patent/PH12017501140A1/en unknown
-
2018
- 2018-04-17 US US15/955,539 patent/US10966963B2/en active Active
-
2019
- 2019-02-18 CL CL2019000431A patent/CL2019000431A1/es unknown
- 2019-11-14 IL IL270653A patent/IL270653B/en unknown
- 2019-12-10 JP JP2019223278A patent/JP7128169B2/ja active Active
-
2020
- 2020-01-21 AU AU2020200407A patent/AU2020200407B2/en active Active
-
2021
- 2021-01-20 AU AU2021200352A patent/AU2021200352B2/en active Active
- 2021-02-25 US US17/185,319 patent/US12233052B2/en active Active
- 2021-11-08 ZA ZA2021/08745A patent/ZA202108745B/en unknown
-
2022
- 2022-03-07 JP JP2022034691A patent/JP7446348B2/ja active Active
-
2024
- 2024-12-18 US US18/985,513 patent/US20250114338A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53837A (fr) | Tetrahydro-pyrido[3,4-b]indoles modulateurs des récepteurs des oestrogènes et leurs utilisations | |
| IL258363B (en) | Tetrahydro-h1-pyrido[4,3-b]indole anti-estrogenic drugs | |
| MA43382A (fr) | Modulateurs des récepteurs des chimiokines | |
| HUE063833T2 (hu) | Tartály és jelzõszerkezet, valamint porlasztó | |
| ZA201800827B (en) | Substituted 4-azaindoles and their use as glun2b receptor modulators | |
| LT3536324T (lt) | 4-okso-3,4-dihidro-1,2,3-benzotriazinai, kaip gpr139 moduliatoriai | |
| DK3126361T3 (da) | Chromen og 1,1a,2,7b-tetrahydrocyclopropa[c]chromen- pyridopyrazindioner som gamma-sekretase-modulatorer | |
| IL250247A0 (en) | History of piperazine as liver x-receptor modulators | |
| DK3145916T3 (da) | Imidazolderivater som formylpeptidreceptormodulatorer | |
| PT3157912T (pt) | Composições parasiticidas compreendendo derivados de indole, seus métodos e suas utilizações | |
| DK2975260T4 (da) | Generatorophængningsanordning | |
| IL252753A0 (en) | History of indole and azaindole, their preparation and use | |
| EP3160746A4 (en) | Dye microenvironment | |
| IL254711A0 (en) | History of Indole | |
| HK40107389A (zh) | 四氢-吡啶并[3，4-b]吲哚雌激素受体调节剂及其用途 | |
| HK40109078A (zh) | 四氢-吡啶并[3，4-b]吲哚雌激素受体调节剂及其用途 | |
| GB201414812D0 (en) | Dynamic flame simulating device |